Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma

Conditions

• Childhood Alveolar Soft Part Sarcoma
• Childhood Angiosarcoma
• Childhood Epithelioid Sarcoma
• Childhood Fibrosarcoma
• Childhood Gliosarcoma
• Childhood Leiomyosarcoma
• Childhood Liposarcoma
• Childhood Malignant Peripheral Nerve Sheath Tumor
• Childhood Synovial Sarcoma
• Previously Treated Childhood Rhabdomyosarcoma
• Recurrent Childhood Rhabdomyosarcoma
• Recurrent Childhood Soft Tissue Sarcoma
• Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
• Recurrent Osteosarcoma
• Rhabdomyosarcoma

Interventions

• BIOLOGICAL: Cixutumumab
• OTHER: Laboratory Biomarker Analysis
• DRUG: Temsirolimus

Sponsor

National Cancer Institute (NCI)